Hubei Meisichuang Pharmaceutical

Hubei Meisichuang Pharmaceutical is a China-based biotechnology company focused on the research and development of innovative small molecule drugs, particularly in the metabolic and endocrine therapeutic areas. The company specializes in developing multi-target agonists, such as GLP-1R/GCGR/GIPR tri-agonists, to treat conditions like type 2 diabetes, obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Headquartered in Wuhan, the firm leverages its medicinal chemistry expertise to advance a pipeline of candidates through early-stage clinical trials. Their lead programs aim to provide more effective and convenient oral or injectable treatments for chronic metabolic diseases.